Mohamed Zakaria Ahmed, Bai Miaoshui, Dong Hanyu, Xue Yang, Jia Feiyong, Feng Junyan
Department of Developmental and Behavioral Pediatrics, Children's Medical Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
The Child Health Clinical Research Center of Jilin Province, Changchun, China.
Nutr J. 2025 Mar 17;24(1):44. doi: 10.1186/s12937-025-01112-w.
Vitamin D₃ has emerged as a potential therapeutic agent for alleviating tic symptoms in children with chronic tic disorders (CTDs). This study aims to evaluate the comparative efficacy of high-dose and low-dose vitamin D₃ supplementation on tic severity and serum 25-hydroxyvitamin D 25(OH)D levels in children with CTDs.
A randomized controlled trial was conducted with 83 children aged 4 to 15 years diagnosed with CTDs. Participants were randomly assigned to receive either high-dose vitamin D₃ (5,000 IU/day) or low-dose vitamin D₃ (1,000 IU/day) for three months. The primary outcome was tic severity, assessed using the Yale Global Tic Severity Scale (YGTSS), while secondary outcomes included changes in serum 25(OH)D and calcium levels. Tic severity and biochemical markers were measured at baseline and after the intervention to assess the effects of vitamin D₃ supplementation.
Both the high-dose and low-dose groups showed significant improvements in tic severity and increases in serum 25(OH)D levels (𝑝 < 0.05). The high-dose group exhibited a significantly greater reduction in tic severity and a more substantial increase in serum 25(OH)D levels compared to the low-dose group (𝑝 < 0.05). No significant differences were observed in serum calcium levels between the group (𝑝 > 0.05). Furthermore, multivariate linear regression analysis revealed a significant negative association between increases in serum 25(OH)D levels and reductions in tic severity (𝑡 = -2.816, 𝑝 < 0.05).
High-dose vitamin D₃ supplementation is more effective than low-dose supplementation in reducing tic severity and increasing serum 25(OH)D levels in children with CTDs. These findings suggest that high-dose vitamin D₃ may serve as a valuable adjunctive therapy for managing CTDs.
维生素D₃已成为缓解慢性抽动障碍（CTD）患儿抽动症状的一种潜在治疗药物。本研究旨在评估高剂量和低剂量补充维生素D₃对CTD患儿抽动严重程度和血清25-羟基维生素D[25(OH)D]水平的比较疗效。
对83名4至15岁被诊断为CTD的儿童进行了一项随机对照试验。参与者被随机分配接受高剂量维生素D₃（5000国际单位/天）或低剂量维生素D₃（1000国际单位/天），为期三个月。主要结局是抽动严重程度，使用耶鲁全球抽动严重程度量表（YGTSS）进行评估，次要结局包括血清25(OH)D和钙水平的变化。在基线和干预后测量抽动严重程度和生化指标，以评估补充维生素D₃的效果。
高剂量组和低剂量组的抽动严重程度均有显著改善，血清25(OH)D水平均升高（p<0.05）。与低剂量组相比，高剂量组的抽动严重程度显著降低，血清25(OH)D水平显著升高（p<0.05）。两组之间的血清钙水平未观察到显著差异（p>0.05）。此外，多变量线性回归分析显示血清25(OH)D水平升高与抽动严重程度降低之间存在显著负相关（t=-2.816, p<0.05）。
在降低CTD患儿的抽动严重程度和提高血清25(OH)D水平方面，高剂量补充维生素D₃比低剂量补充更有效。这些发现表明，高剂量维生素D₃可能是治疗CTD的一种有价值的辅助疗法。
